iBio develops and offers product applications of its proprietary iBioLaunch and iBioModulator platforms. In addition, the company develops select vaccine candidates that have been derived from its iBioLaunch platform. Its technology utilizes transient gene expression in unmodified green plants for the development and production of biologics.
The company announced today the production of a vaccine candidate for the recently emerged H7N9 influenza virus (first appeared in China) by an independent third-party laboratory using its BioLaunch platform. This accomplishment took only 21 days as measured from the initial antigen sequence information to purification of recombinant protein.
iBio's BioLaunch platform eliminates the need to culture cells under sterile conditions, removes uncertainty about yield consistency for large production volumes, and, subject to regulatory approval, can possibly deliver vaccine doses for emergency use against a pandemic or bio-terrorism threat. The platform has been used successfully before to produce vaccine-quality antigens associated with a range of influenza strains including H7N7, H5N1, H3N2, H1N1, and a variety of influenza B strains.
The company's iBioLaunch platform is a step ahead of current conventional approaches. It eliminates the months involved in the development and production of regular vaccines for viruses. Patient care now often involves only isolation of patients and supportive care. For further information about iBio and its technologies, please visit ibioinc.com.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net